Pharma Equity Group
0.251 DKK -1.95%HC Andersen Capital receives payment from Pharma Equity Group for a DigitalIR/Corporate Visibility agreement. See disclaimer.
11 investors are following this company
Pharma Equity Group develops new medicines for the local treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The company uses repositioning of existing drugs and brings drug candidates to a clinical phase III stage, after which it is handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the company.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
PEG
Daily low / high price
0.245 / 0.259
DKK
Market cap
256.76M DKK
Turnover
178.48K DKK
Volume
710K
Latest research
Extensive report
Inderes' extensive report is an investor's handbook on customer companies covered by our research.
The latest extensive report was released
Read the reportAnalyst
Claus Thestrup
CEO, Sweden
Latest videos
Financial calendar
Interim report
16.05.2024
Interim report
16.08.2024
Interim report
15.11.2024
ShowingAll content types
Pharma Equity Group (One-pager): Continues to move forward but the shares continues to slide
Dagens aktienyheder 24/04: Pharma Equity Group A/S, BioPorto A/S, NTG | Nordic Transport Group A/S , ExpreS2ion Biotechnologies og MapsPeople
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools